Do selective serotonin receptor inhibitor antidepressants reduce tamoxifen's effectiveness and increase the risk of death from breast cancer?

被引：0
|
作者：
Kathleen I Pritchard
机构：
[1] Sunnybrook Odette Cancer Centre,
来源：
Breast Cancer Research | / 12卷
关键词：
Tamoxifen; Fluoxetine; Sertraline; Venlafaxine; Fluvoxamine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 43 条
  • [41] EMERALD: A randomized, open-label, phase III trial to evaluate the efficacy and safety of elacestrant (RAD1901), a novel oral selective estrogen receptor degrader (SERD), vs investigator's choice of endocrine therapy for ER+/HER2-advanced breast cancer following CDK4/6 inhibitor therapy
    Bardia, A.
    Lu, J.
    Kaklamani, V.
    Jung, J.
    Anderson-Villaluz, A. T.
    Conlan, M. G.
    Bidard, F-C.
    Cortes, J.
    Aftimos, P. G.
    ANNALS OF ONCOLOGY, 2020, 31 : S80 - S80
  • [42] EMERALD: A randomized, open-label, phase 3 trial to evaluate the efficacy and safety of elacestrant (RAD1901), a novel oral selective estrogen receptor degrader (SERD), vs investigator's choice of endocrine therapy for ER+/HER2-advanced breast cancer following CDK4/6 inhibitor therapy
    Aftimos, Philippe
    Bardia, Aditya
    Kaklamani, Virginia G.
    Lu, Janice
    Bihani, Teeru
    Jung, JungAh
    Anderson-Villaluz, Alfred T.
    Conlan, Maureen G.
    Cortes, Javier
    CANCER RESEARCH, 2020, 80 (04)
  • [43] Results from a phase III randomized, placebo-controlled clinical trial evaluating adjuvant endocrine therapy +/-1 year of everolimus in patients with high-risk hormone receptor-positive, HER2-negative breast cancer: SWOG S1207
    Chavez, Marianna
    Miao, Jieling
    Pusztai, Lajos
    Goetz, Matthew P.
    Rastogi, Priya
    Ganz, Patricia A.
    Mamounas, Eleftherios
    Paik, Soonmyung
    Bandos, Hanna
    Razaq, Wajeeha
    O'Dea, Anne
    Kaklamani, Virginia
    Silber, Andrea L. M.
    Flaum, Lisa E.
    Andreopolu, Eleni
    Baar, Joseph
    Wendt, Albert G.
    Carney, Jennifer F.
    Sharma, Priyanka
    Gralow, Julie R.
    Lew, Danika L.
    Barlow, William E.
    Hortobagyi, Gabriel N.
    CANCER RESEARCH, 2023, 83 (05)
12345